Annual Meeting Abstract Submissions

Conceptual. Theoretical. Intellectual. Imaginative. Academic.

These words define abstract as existing in thought, or as an idea, not having a physical or concrete existence.

USCAP defines abstract as the synoptic summary of your intellectual focus or research investigation. Convert your thought or idea into something concrete.

The abstract submission site is closed.

Notification of acceptance and rejection are available in your abstract account.

Requirements

Scientific material must be original and not previously published, nor currently accepted for publication or presentation at another meeting prior to the USCAP 2020 Annual Meeting.

Abstract Fee

There is a $50 non-refundable processing fee for each abstract submission.

Submission Deadline

The deadline to submit abstracts was Thursday, September 26, 2019 at 3:00 PM Eastern Daylight Time. The submission site is closed.

USCAP Embargo Policy

Unless otherwise noted, all abstracts presented at the USCAP Annual Meeting are embargoed until the date and time of presentation. They cannot be presented in any national or international forum or be published (online of print) in abstract or manuscript form prior to first day of the USCAP annual meeting. USCAP reserves the right to lift the embargo on specific abstracts that are selected for promotion prior to or during the USCAP Annual Meeting.

Eligibility Requirements

Scientific material must be original. It cannot be previously published in abstract or manuscript form. It also cannot be currently accepted for publication or presented at another meeting prior to the USCAP 2020 Annual Meeting, February 29-March 5, 2020. You may submit as many abstracts as you wish; there is no limit to the number of co-authored abstracts. However, no more than three abstracts will be accepted from any first author. If more than three first-author abstracts are submitted, the lowest scoring abstract will be immediately rejected. Abstracts are reviewed in a blinded fashion. Please do not include any identifying information such as institutional names or specific names for institutional assays, in the body of the abstract. View the complete rules and submission guidelines below.

All abstracts submitted to the USCAP 2020 Annual Meeting must meet the eligibility requirements below:

  • Scientific material must be original.
  • Abstracts are not eligible for consideration if the paper has been presented at a major national or international meeting prior to the USCAP 2020 Annual Meeting, February 29-March 5, 2020.
  • Abstracts cannot be previously published, online or in print, prior to the USCAP 2020 Annual Meeting, February 29-March 5, 2020.
  • If the accepted abstract is also submitted as a manuscript for publication prior to the USCAP 2020 Annual Meeting, the authors are responsible for coordinating with the journal to determine a publication date that abides by the Academy’s embargo policy. Abstracts related to manuscripts that are published online or in print before the USCAP 2020 Annual Meeting, February 29-March 5, 2020, must be withdrawn. Please notify the Academy via e-mail at support@uscap.org.
    • If you choose to submit a manuscript to the Modern Pathology or Laboratory Investigation prior to the abstract presentation at the USCAP 2020 Annual Meeting, February 29-March 5, 2020, you will need to indicate this on your submission form and in the cover letter of your journal submission. USCAP has an agreement with these journals to withhold approved manuscripts from publication until the embargo is lifted.
  • All abstracts must follow USCAP’s embargo policy. Any abstract found to be presented or published prior to the USCAP 2020 Annual Meeting, February 29-March 5, 2020 will be removed from the program.
  • USCAP will examine all abstracts with anti-plagiarism software to verify the originality of the work. Flagged abstracts will be manually reviewed and those that represent only an incremental advance or lack sufficient novelty compared with published abstracts will be rejected.

Author Eligibility

  • Individuals may submit as many abstracts as they wish; however, no more than three abstracts will be accepted from any first author. If more than three first author abstracts are submitted, only the three highest scored abstracts will be accepted.
  • Individuals may serve as a coauthor on an unlimited number of abstracts.
Submission Requirements

 for the Contact Information

Provide your full name, academic degree(s), institution, address (including city and country), and email address. Only the first author and primary contact will receive future correspondence from USCAP regarding the status of the abstract.

To ensure all authors are able to receive email correspondence from USCAP, please add the following domain to your email software.

  • xcdsystem.com

Co-Authors

  • The full name, institution, city, state, country, and email is required for all co-authors.
  • Upon entry of an author, an automatic email is sent from the system requesting the author login and complete a disclosure. The primary contact and first author are responsible for ensuring all authors complete their disclosures prior to closure of the submission website on Thursday, September 26, 2019 at 3:00 PM Eastern Daylight Time.
  • Authors can complete their disclosures at any point after being added to the system up to the closure of the submission website. If you are submitting an abstract for a platform presentation, it is the responsibility of the first author to ensure all authors have completed their disclosure. If any author disclosures are missing at the closure of the submission website, the abstract will automatically default to a poster presentation.
  • If authors do not receive the email, they can simply login to the system, scroll down to locate the abstract, and select the Disclosures button. It will be red if the disclosure(s) are incomplete.

Abstract Title

  • The abstract title must be in Title Case.
    • Capitalize the first word of the title.
    • Capital letters should be used for all nouns, verbs, adjectives, adverbs, and pronouns, and subordinate conjunctions (e.g. because, although). All other words, including articles, coordinate conjunctions (e.g. and, or, but), and prepositions should be lowercase.
    • Do use lowercase and uppercase letters in instances when they have specific meanings (e.g. mCEA, HER2).
  • Do not include a period at the end of the title.
  • The maximum length of the abstract title is 40 words.

    EXAMPLE

    Correct: Utility of p53 and mCEA Immunostaining in Biliary Cytology Specimens
    Incorrect: Utility of p53 and mcea Immunostaining in biliary cytology specimens.

    Abstract Content

    • The maximum length of the abstract is 2500 characters (including spaces). This includes the background, design, results, and conclusion. The program will not allow you to submit your abstract unless it fits the defined space. There is no limit on the number of authors. Authors and their affiliations will not deduct from the character count on the abstract.
    • The abstract should be divided into the following: Background, Design, Results, and Conclusion. The submission program provides you with the ability to enter information in each of these sections and displays them on the final abstract form in this manner. These headings appear automatically – do not type them in.Abstracts are blinded for review. Please do not include identifying information in the body of the abstract (e.g. institutional names or assays).
    • Tables and figures are permitted in addition to text allotments described above. Guidelines are below:
      • Figures
        Maximum of 2 figures per abstract submission
        Width – 6 inches
        Height – no more than 4 inches tall
        Maximum file size cannot exceed 3MB
        Images must be high resolution, 300 DPI, RGB
        Only jpg (jpeg) or png formats are allowed
        Once you upload a Figure, you can update it by uploading a different file to the same location or delete by selecting the Delete Figure button.
      • Table
        Maximum of 1 table per abstract submission. Text in the table will not deduct from the character count.
        Width – 6 inches
        Height – no restrictions
        Font – Helvetica/Arial no less than 5pt
    • Standard abbreviations are acceptable. A special abbreviation should be placed in parentheses after the first appearance of the full word for which it stands. Greek and mathematical symbols are provided in the character map within the program.
    • Generic drug names are preferred and should be written without capital letters. If a proprietary drug name is used, the first letter should be capitalized.
    • Abstracts can be edited up to the point of the submission deadline and closure of the abstract submission site on Thursday, September 26, 2019 at 3:00 PM, Eastern Daylight Time. There is no final submit button.
    • Abstracts revisions cannot be made after the submission deadline.

      Presentation Type

      Check Poster Only or Either Poster or Platform on the Submit Abstract page. Abstracts submitted for poster or platform presentation will be assigned to a category by the Abstract Assignment Committee. Assignments reflect the scientific merit of the abstract and the Committee’s opinion regarding the most effective presentation method.

      Poster Presentations – There are six poster sessions over the course of three days. Posters will be on display for half days on Monday, Tuesday or Wednesday. Authors are expected to be at their posters during the morning and afternoon breaks.

      Date Time of Break
      Monday, March 2 9:30 – 11:00 AM
      3:00 – 4:30 PM
      Tuesday, March 3 9:30 – 11:00 AM
      2:45 – 4:00 PM
      Wednesday, March 4 9:30 – 11:00 AM
      2:30 – 4:00 PM

      Platform Presentations – Each platform presentation is limited to fifteen (15) minutes, this includes ten (10) minutes for the presentation and five (5) minutes for questions. All platform presentations must utilize digital/electronic projection using Microsoft PowerPoint. A PowerPoint template will be provided after acceptance.

      Category

      Abstracts must be submitted in one of the categories listed below. Abstracts submitted to an inappropriate category will be reassigned accordingly. See Category Descriptions for detailed information.

      • Autopsy
      • Bone and Soft Tissue Pathology
      • Breast Pathology
      • Cardiovascular Pathology
      • Cytopathology
      • Dermatopathology
      • Education
      • Endocrine Pathology
      • Gastrointestinal Pathology
      • General Surgical Pathology
      • Genitourinary Pathology (including Renal tumors)
      • Gynecologic and Obstetric Pathology
      • Head and Neck Pathology
      • Hematopathology
      • Infectious Disease Pathology
      • Informatics
      • Liver Pathology
      • Medical Renal Pathology (including Transplantation)
      • Neuropathology and Ophthalmic Pathology
      • Pancreas, Gallbladder, Ampulla, and Extra-Hepatic Biliary Tree
      • Pathobiology and Emerging Techniques
      • Pediatric and Perinatal Pathology
      • Pulmonary, Mediastinum, Pleura, and Peritoneum Pathology
      • Quality and Patient Safety

      Abstracts may be moved from the category of submission to another category by the Abstract Assignment Committee as appropriate.

      Awards

      Stowell-Orbison Awards and Autopsy or Surgical Pathology Awards for Pathologists-in-Training

      Application information must be completed online through the abstract submission system. In order to be eligible for these awards, applicants must meet all of the following requirements:

      • First author must be a pathologist-in-training
      • Applicants can submit only one first-author abstract for award consideration
      • Upload a verification of eligibility

      Detailed award information is available here: https://www.uscap.org/stowell-orbison-awards/

      Abstracts accepted for consideration of Stowell-Orbison Awards and/or the Surgical and Autopsy Pathology Awards, will be presented as posters on Monday morning of the USCAP Annual Meeting. Abstracts that are submitted for this competition, but not accepted, will automatically be considered for acceptance as a regular abstract according to subspecialty.

      Category Descriptions

      Autopsy: This category includes abstracts describing pathology related to adult autopsy. It excludes abstracts describing pediatric autopsy, fetal pathology, and autopsy-related neuropathology.

      Bone and Soft Tissue Pathology: This category includes abstracts describing neoplastic and non-neoplastic diseases of soft tissues and bone. It does not include abstracts describing cutaneous soft tissue tumors or mesenchymal tumors of the gastrointestinal tract.

      Breast Pathology: This category includes abstracts describing neoplastic and non-neoplastic diseases of the breast. Abstracts describing mesenchymal tumors and hematopoietic disorders of the breast are included.

      Cardiovascular Pathology: This category includes abstracts describing neoplastic and non-neoplastic diseases of the heart and blood vessels. Cardiac transplantation pathology is included.

      Cytopathology: This category includes abstracts describing neoplastic and non-neoplastic diseases of all sites encountered in exfoliative or fine needle aspiration samples.

      Dermatopathology: This category includes abstracts describing neoplastic and non-neoplastic diseases of the skin. Abstracts describing cutaneous mesenchymal and hematopoietic tumors are included.

      Education: This category includes abstracts describing innovation and application of existing platforms (e.g. social media) to pathology education. Topics may be related to specific organ systems or general anatomic pathology.

      Endocrine Pathology: This category includes abstracts describing diseases of the thyroid gland, parathyroid glands, adrenal glands, and paraganglia. It does not include abstracts describing disorders of the pancreas, endocrine tumors of the gastrointestinal tract, or pituitary diseases.

      Gastrointestinal Pathology: This category includes abstracts describing neoplastic and non-neoplastic diseases of the tubular gastrointestinal tract. Abstracts describing mesenchymal tumors (e.g. gastrointestinal stromal tumor) and bowel transplantation pathology are included. This category excludes abstracts describing diseases of the gallbladder, pancreas, liver, ampulla, and extrahepatic biliary tree.

      General Surgical Pathology: This category includes abstracts describing neoplastic and non-neoplastic diseases that are not limited to one organ system (e.g. molecular analysis of squamous cell carcinomas from different sites, or novel immunohistochemical markers that have diagnostic applications to multiple sites).

      Genitourinary Pathology: This category includes abstracts describing neoplastic diseases of the kidneys, as well as both neoplastic and non-neoplastic disorders of the ureters, urinary bladder, prostate, penis, and testis. This category does not include abstracts describing medical renal disease or transplantation pathology.

      Gynecologic Pathology: This category includes abstracts describing neoplastic and non-neoplastic diseases of the ovaries, fallopian tubes, uterus, cervix, vagina, and vulva. It also includes abstracts describing placental and obstetric pathology. It does not include abstracts describing primary peritoneal neoplasms.

      Head and Neck Pathology: This category includes abstracts describing neoplastic and non-neoplastic diseases of the oral cavity, nasopharynx, paranasal sinuses, larynx, and salivary glands. It does not include abstracts describing cutaneous diseases of the face or disorders of the thyroid and parathyroid glands.

      Hematopathology: This category includes abstracts describing neoplastic and non-neoplastic diseases of lymph nodes, bone marrow elements, spleen, and dendritic cells. It does not include thymoma or thymic carcinoma. Abstracts describing disorders involving specific sites (e.g. skin, gastrointestinal tract, central nervous system) may be more appropriately submitted to other categories.

      Infectious Disease Pathology: This category includes abstracts describing non-neoplastic diseases of an infectious etiology that affect multiple organs or organ systems. Abstracts describing disorders confined to one organ or organ system (e.g. pulmonary fungal infections) and those discussing pathogen-driven neoplasia may be more appropriately submitted to other categories.

      Informatics Pathology: This category includes abstracts describing issues related to pathology information systems, digital pathology, data analysis, information technology, machine learning, and similar topics. Abstracts describing application of these techniques to pathology education or diseases of one organ and/or one organ system may be more appropriately submitted to other categories.

      Liver Pathology: This category includes abstracts describing neoplastic and non-neoplastic diseases of the liver. Liver transplantation pathology and tumors and inflammatory conditions of the intrahepatic bile ducts are included. Disorders of the extrahepatic bile ducts and gallbladder are excluded.

      Medical Renal Pathology: This category includes abstracts describing issues related to non-neoplastic renal diseases as well as transplantation pathology. It does not include abstracts describing neoplastic diseases of the kidney.

      Neuropathology and Ophthalmic Pathology: This category includes abstracts describing neoplastic and non-neoplastic diseases of the central nervous system and its coverings, pituitary gland, and eye. Autopsy neuropathology is included. Abstracts describing myopathies and peripheral neuropathies are included.

      Pancreas, Gallbladder, Ampulla and Extra-hepatic Bile Ducts: This category includes abstracts describing neoplastic and non-neoplastic diseases of the pancreas, gallbladder, ampulla, and extra-hepatic bile ducts up to the hilum. Endocrine/neuroendocrine tumors of the pancreas and pancreatic transplantation pathology are included.

      Pathobiology and Emerging Techniques: This category includes abstracts that emphasize disease biology or describe issues related to oncogenesis and pathogenesis of non-neoplastic conditions and highlights new assays and platforms that may have diagnostic or prognostic value in the pathologic assessment of human diseases. Pan-genomic/pan-proteomic approaches and ultrastructural pathology are generally included, although abstracts describing application of these techniques to diseases of one organ or one organ system may be more appropriately submitted to other categories.

      Pediatric and Perinatal Pathology: This category includes abstracts describing neoplastic and non-neoplastic diseases of the pediatric population, perinatal diseases, and fetal autopsies.

      Pulmonary, Mediastinum, Pleura, and Peritoneum: This category includes abstracts describing neoplastic and non-neoplastic diseases of the tracheobronchial tree, lungs, pleura, and mesothelial surfaces of the peritoneal cavity. It also includes thymoma, thymic carcinoma, and mediastinal germ cell tumors. It does not include lymphomas.

      Quality and Patient Safety: This category includes abstracts describing the study of risk to patients in pathology as well as failure to meet standards of timeliness, report accuracy, and transfer of materials between services. It includes abstracts describing baseline data collection followed by an intervention and analysis of post-implementation data.

      Abstracts may be moved from the category of submission to another category by the Abstract Assignment Committee as appropriate.

      Financial Disclosures

      USCAP has zero tolerance for any commercial bias in abstracts and the content must be presented objectively. Reviewers are instructed to reject any abstract which does not meet these criteria.

      • Each author must complete an Author Disclosure Form for each abstract submitted; this can be done as soon as the author has been added to an abstract. The abstract does NOT need to be final in order to submit a disclosure.
      • Upon entry of an author, an automatic email is sent from the system requesting the author login and complete a disclosure. The first author is responsible for ensuring all authors complete their disclosures.
      • No abstract will be accepted for a platform presentation without completed disclosure forms from ALL authors. Authors must note any relevant relationships with companies whose products and/or services are discussed in the abstract. All relationships will be disclosed to the audience.

      This policy is not intended to prevent authors with commercial relationships from making a presentation. Disclosure is required to help maintain objectivity and allow audience members to form their own judgments regarding the merit of material presented with the benefit of full disclosure of facts.

      Policy on Unlabeled/Off-Label Use
      USCAP has determined that disclosure of unlabeled/off-label or investigational use of commercial product(s) is informative for audiences and therefore requires this information to be disclosed to the learners at the beginning of the presentation. Uses of products discussed in this educational activity may not be the same as those indicated in product labeling approved by the Food and Drug Administration (FDA). USCAP requires that any discussions of such “off-label” use be based on scientific research that conforms to generally accepted standards of experimental design, data collection, and data analysis. All references to unlabeled/off-label use of products in the abstract must be disclosed on the poster when presented.

      Abstracts from Industry
      Abstracts that are accepted will be presented as posters and must only display research findings. No advertising or product identification by brand name is allowed. Commercial, product, and company logos cannot be placed on posters or poster boards. Posters that contain any type of commercial promotion, as described above, will be removed from the poster hall immediately without notice to the presenter.

      All posters presented by industry must include a disclosure statement.

      Abstract Fee

      There is a $50 non-refundable processing fee for each abstract submission. Credit card payment must be made by selecting the Payment button. Payment must be made in order to complete the submission process. The abstract submission fee does not include general registration. If accepted, the presenting author of the abstract must register for the 2020 USCAP Annual Meeting.

      Notification of receipt will be emailed to the primary contact following the payment. NOTE: It is your responsibility to contact USCAP if you do not receive confirmation of abstract receipt within 1 business day. USCAP will be able to confirm receipt of your abstract or will assist you to ensure that your abstract has been completed.

      Submission Deadline and Notifications

      Deadline

      Only electronic submissions of original work will be accepted. To be eligible for review:

      • Submission must be received by Thursday, September 26, 2019 at 3:00 PM Eastern Daylight Time
      • The abstract fee must be paid prior to the abstract deadline. If the payment is not received by the deadline, the abstract will be withdrawn.
      • All authors and co-authors must have completed an Author Disclosure Form for each abstract.

      Notifications

      Notification of acceptance or rejection will be sent to the first author and primary contact by e-mail in early November; authors will not receive any notifications by mail. A second notification specifying presentation type and further details about the presentation will be sent to the first author and primary contact in late November. If you do not receive an e-mail by mid-December please login to the Abstract Submission site with the login credentials used to create the submission and select the View Final Status button.

      If an abstract is accepted, the presenting author is required to register for the USCAP 2020 Annual Meeting and pay the general registration fee. Online registration will be available on the USCAP website November 1, 2019. All registrations must be completed online. Register early as fees for early registration are discounted.

      Publication of Abstracts in Modern Pathology and Laboratory Investigation

      All abstracts accepted for presentation at the 2020 USCAP Annual Meeting are published in an online-only supplement of Modern Pathology and Laboratory Investigation. The supplement will be released on Monday, March 2, 2020.

      Abstract Withdrawal

      To withdraw an abstract, the primary contact or first author must contact USCAP Education at education@uscap.org with the request. Abstracts withdrawn after December 20, 2019 will not be included in the online program, but the abstract will be published in the Modern Pathology and Laboratory Investigation journal supplements.

      USCAP Embargo Policy

      Unless otherwise noted, all abstracts accepted for presentation at the USCAP Annual Meeting are embargoed from submission until the date and time of presentation. They cannot be presented in any national or international forum or be published (online or print) in abstract or manuscript form prior to the first day of the USCAP annual meeting. USCAP reserves the right to lift the embargo on specific abstracts that are selected for promotion prior to or during the USCAP Annual Meeting.

      If the accepted abstract is also submitted as a manuscript for publication, authors are responsible for coordinating a publication date that abides by the Academy’s embargo policy. If publication occurs online or in print before the USCAP 2020 Annual Meeting, February 29-March 5, 2020, the abstract must be withdrawn. Please notify the Academy via e-mail at support@uscap.org.

      Frequently Asked Questions

      What is the abstract submission deadline?

      Abstract submissions will open on Wednesday, August 14, 2019. Abstracts are due Thursday, September 26th at 3:00 PM Eastern Daylight Time. A completed abstract must include the following:

      • Abstract Title, Background, Design, Results, and Conclusion
      • Completed Payment
      • To be considered for a platform presentation, all author disclosures must have been completed. Each author will need to submit a disclosure for each abstract.
      How do I get my login information to submit an abstract?
        • Emails regarding login information or disclosures may be blocked by your institutions spam blocker. Please ask your institution’s Information Technology staff to “white list” any emails coming from uscap.org and xcdsystem.com.
        • In order to login visit the abstract submission site and enter your email address and password.
        • If you do not remember your password, click Reset Password on the submission login page. If you no longer have access to the email associated with your account, please email support@uscap.org or call USCAP offices: at +1-706-733-7550
      How do I update my contact information?
      • Once you are logged in, click Profile Home in the upper left of the abstract submission site, then select Update Profile.
      • Select the Update Profile button at the bottom to save your changes.
      Do I need to add section headings or are they added automatically?
      No, you do not need to add section headings. The headers (Background, Design, Results, Conclusion) will be added automatically in the publication of abstracts.
      How do I edit my abstract?
      • Login to the abstract submission site and select the Edit Abstract button to make necessary changes.
      • Then click the Update Abstract button to save your changes.
      • There is no final submit button. Abstracts can be edited up until the submission deadline on Thursday, September 26 at 3:00 PM Eastern Daylight Time.
      How do I edit or delete a figure/image?
      • To edit a figure/image: select the figure you would like to edit, and select a new file. The new file will override the existing file.
      • To delete a figure: select the delete figure button under the figure and scroll to the bottom and select Update Abstract. Note, the delete figure button will only appear after the abstract has been saved.
      Do images or tables take away from the character limit?

      No. Authors will have 40 words to complete the abstract title. Authors will have 2500 characters (including spaces) to complete the abstract background, design, results, and conclusion. Text in the results table will not deduct from the character count.

      I did not receive an email to complete my disclosure, how do I complete it?
      • Emails may be blocked by your institutions spam blocker. Please ask your institutions Information Technology staff to white list any emails coming from uscap.org and xcdsystem.com.
      • Also, co-authors may login to complete their disclosures.
      • Once logged in, click on the 2020 Annual Meeting Abstract Submission button
      • Then scroll down and click on the Author Disclosure button. It will be red if the disclosure(s) are incomplete.
      • Follow the prompts to complete and submit your disclosure.
      How do I complete disclosures as primary presenter?
      • Once you have submitted your abstract, the Author Disclosure button will turn red and become active.
      • Select this button and follow the prompts to complete your disclosure.
      • You cannot complete disclosures for the co-authors on your abstract. Each of the co-authors will need to login to the system and complete their own disclosures.
      • To be considered for a platform presentation, all author disclosures must have been completed. If any author disclosures are missing at the time of closure of the submission website, the abstract will automatically default to a poster presentation.
      How do I see which co-authors have completed their disclosures?

      Only primary presenters can check the status of co-author disclosures. Follow the steps below to find out which co-authors have completed their disclosures.

      • Login to view your abstract
      • Once logged in, click on 2020 Annual Meeting Abstract Submission
      • Scroll down to view your abstract
      • Select View Disclosures
      • A screen will pop-up showing all the co-authors and their disclosure status
      • To be considered for a platform presentation, all author disclosures must have been completed.
      How do I pay for and submit my abstract?
      • Visit the login page.
      • Enter your email address and password to login.
      • Once you are logged in, click on the 2020 Annual Meeting Abstract Submission button.
      • Scroll down and click on Payment
      • Follow the prompts to enter your payment information and submit.
      • The submission fee for each abstract is $50 USD.
      • A abstract submission is not considered Complete until the submission fee is paid. After paying the submission fee, you can still update your abstract until the deadline: Thursday, September 26, 2019 at 3:00 PM Eastern Daylight Time.

      NOTE: There is no final submit button. Once the payment and all author disclosures are received, the abstract is considered complete. You may edit your abstract until the submission site closes on Thursday, September 26, 2019 at 3:00 PM Eastern Daylight Time.

      How do I get a receipt for my payment?
      • Visit the login page.
      • Enter your email address and password to login.
      • Once you are logged in, click on the 2020 Annual Meeting Abstract Submission button.
      • Scroll down and click on Payment Receipt.